Antisense oligonucleotides for the treatment of Leber congenital amaurosis
Robert Wilhelmus Johanna Collin, Venlo (NL); Franciscus Peter Maria Cremers, Malden (NL); and Antonia Ingrid Den Hollander, Groesbeek (NL)
Assigned to Stichting Radboud universitair medisch centrum, Nijmegen (NL)
Filed by Stichting Radboud universitair medisch centrum, Nijmegen (NL)
Filed on Feb. 23, 2022, as Appl. No. 17/678,433.
Application 17/678,433 is a continuation of application No. 16/842,157, filed on Apr. 7, 2020, granted, now 11,279,933.
Application 16/842,157 is a continuation of application No. 16/197,865, filed on Nov. 21, 2018, granted, now 10,647,985, issued on May 12, 2019.
Application 16/197,865 is a continuation of application No. 15/963,229, filed on Apr. 26, 2018, granted, now 10,167,470, issued on Jan. 1, 2019.
Application 15/963,229 is a continuation of application No. 15/656,635, filed on Jul. 21, 2017, abandoned.
Application 15/656,635 is a continuation of application No. 14/342,776, granted, now 9,771,580, issued on Sep. 26, 2017, previously published as PCT/NL2012/050275, filed on Apr. 25, 2012.
Claims priority of provisional application 61/531,137, filed on Sep. 6, 2011.
Claims priority of application No. 2007351 (NL), filed on Sep. 5, 2011.
Prior Publication US 2022/0235355 A1, Jul. 28, 2022
1. An antisense oligonucleotide that is capable of modulating splicing of CEP290 c.2991+1655A>G, wherein the antisense oligonucleotide has a length of 8 to 128 nucleotides and has 90% to 100% complementarity to a sequence within SEQ ID NO:6, and wherein said antisense oligonucleotide comprises one or more modifications to increase nuclease resistance.